http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2646599-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1544e86240adcd61124126cf7f1d9948 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-04 |
| filingDate | 2013-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9baadda4d3ccf9741c2f00b4d8d310bf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee1c3871f6e55feafd1a6506cd31050c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62e7a284af6dcc20de9b8ba76fd40330 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d357b63014e3a03c755ba916cfa7119 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6e50135ad97b33c20dab060534b607b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c83722faf4db08385fdaabb0e62f19fb |
| publicationDate | 2018-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2646599-C2 |
| titleOfInvention | Crystalline forms of the dihydropyrimidin derivatives |
| abstract | FIELD: chemistry. n SUBSTANCE: invention refers to the crystalline form of the formula (I) compound, wherein the crystalline form is form B, form C, form H or form I. Crystalline form B has the X-ray powder diffraction (XRPD) model, which includes peaks that are expressed in degrees 2θ at 6.68°±0.2°, 13.39°±0.2°, 19.65°±0.2°, 20.26°±0.2°, 22.45°±0.2°, 24.80°±0.2°, 25.01°±0.2°, 26.19°±0.2°, 26.61°±0.2° and 28.79°±0.2°. Crystalline form C has the X-ray powder diffraction (XRPD) model, which includes peaks that are expressed in degrees 2θ at 5.39°±0.2°; 13.25°±0.2°; 16.00°±0.2°; 17.27°±0.2°; 21.33°±0.2°; 21.92°±0.2°; 22.53°±0.2°; 23.47°±0.2°; 26.56°±0.2°; 26.87°±0.2°; 29.41°±0.2° and 32.22°±0.2°. Crystalline form of H has the X-ray powder diffraction (XRPD) model, which includes peaks that are expressed in degrees 2θ at 7.58°±0.2°; 10.29°±0.2°; 12.00°±0.2°; 19.07°±0.2°; 19.93°±0.2°; 20.78°±0.2°; 21.33°±0.2°; 21.48°±0.2°; 24.76°±0.2°; 25.59°±0.2°; 25.82°±0.2°; 26.01°±0.2° and 26.58°±0.2°. Crystalline form is Form I, has a powder X-ray diffraction (XRPD) model including peaks expressed in degrees 2θ at 9.41°±0.2°; 17.59°±0.2°; 21.37°±0.2°; 21.72°±0.2°; 22.15°±0.2°; 22.50°±0.2°; 23.90°±0.2°; 24.59°±0.2°; 24.99°±0.2°; 26.32°±0.2°; 27.09°±0.2°; 29.68°±0.2° and 30.53°±0.2°. n EFFECT: crystalline forms of the mesylate salt of 6-[R,S]-ethyl-6-(2-bromo-4-fluorophenyl)-4-(morpholinomethyl)-2-(thiazol-2-yl)-1,6-dihydropyrimidin-5-carboxylate, which are characterized by excellent solubility, stability. n 15 cl, 12 dwg, 3 tbl, 9 ex |
| priorityDate | 2012-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 64.